XSTOMODTX
Market cap6mUSD
Dec 23, Last price
1.97SEK
1D
3.68%
1Q
17.26%
IPO
-61.82%
Name
Modus Therapeutics Holding AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.96%
Rev. gr., 5y
%
Revenues
0k
Net income
-18m
L-2.31%
CFO
-17m
L-23.20%
Earnings
May 16, 2025
Profile
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 16,313 | 17,886 | 20,638 | |||
Unusual Expense (Income) | ||||||
NOPBT | (16,313) | (17,886) | (20,638) | |||
NOPBT Margin | ||||||
Operating Taxes | (18) | 1,000 | ||||
Tax Rate | ||||||
NOPAT | (16,313) | (17,868) | (20,639) | |||
Net income | (17,897) -2.31% | (18,320) -11.46% | (20,692) 243.84% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 19,365 | 33,126 | ||||
BB yield | -62.72% | -70.44% | ||||
| Debt | ||||||
Debt current | 11,500 | |||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 12,861 | |||||
Net debt | (19,110) | 1,026 | (20,698) | |||
| Cash flow | ||||||
Cash from operating activities | (16,684) | (21,724) | (16,078) | |||
CAPEX | ||||||
Cash from investing activities | (50) | |||||
Cash from financing activities | 25,320 | 11,500 | 29,431 | |||
FCF | (16,313) | (17,868) | (20,639) | |||
| Balance | ||||||
Cash | 19,060 | 10,424 | 20,648 | |||
Long term investments | 50 | 50 | 50 | |||
Excess cash | 19,110 | 10,474 | 20,698 | |||
Stockholders' equity | (315,217) | (298,511) | (280,191) | |||
Invested Capital | 332,899 | 307,390 | 295,925 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 17,745 | 16,100 | 12,376 | |||
Price | 1.74 -37.63% | 2.79 -26.58% | 3.80 | |||
Market cap | 30,876 -31.26% | 44,919 -4.49% | 47,029 | |||
EV | 11,766 | 45,945 | 26,331 | |||
EBITDA | (16,313) | (17,886) | (20,638) | |||
EV/EBITDA | ||||||
Interest | 1,496 | 314 | 1,000 | |||
Interest/NOPBT | ||||||